"Will the way PrEP is explained impact understanding and risk perception?"

Pre-Exposure Prophylaxis (PrEP) is a strategy that involves the use of anti-HIV medications (also called antiretrovirals, or ARVs) by HIV-negative individuals to reduce the risk of HIV infection via sexual exposure. In 2012, the US Food and Drug Administration (FDA) approved the drug, Truvada, for daily oral use as PrEP.

PrEPARE NYC (PrEP Awareness, Research, and Education for New York City) is designed to examine different ways of presenting information about PrEP to people who might be interested in using it and to find out what types of messages have the best impact on understanding, acceptability, and risk perception. We want to raise awareness about PrEP among men in NYC and learn from them about what they need to make decisions about their health.



Funded by:
The National Institute of Mental Health (NIMH)
Grant #: R01MH095565
Dates: 09/2011 - 06/2014
PI: Sarit A. Golub, PhD, MPH